Prior treatments influence immunotherapy response in advanced melanoma

April 24, 2023
Findings may help scientists create more precise future treatments and predict which patients will benefit most from current immune checkpoint blockade.

Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy – CTLA-4 blockade – as well as other factors.

Their findings, based on analysis of seven data sets generated over the past decade, which included results of tumor biopsies from more than 500 patients, are published in Cancer Cell.

UCLA release

ID 90790743 © Rido | Dreamstime.com
dreamstime_xxl_90790743_1
By Rawpixel.com on Adobe Stock
adobestock_137153252
By Jesse B/peopleimages.com on Adobe Stock
adobestock_557096555
By Pixel-Shot on Adobe Stock
adobestock_224306882